Article metrics

Download PDFPDF

Original research
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

 

Online download statistics by month:

Online download statistics by month: April 2021 to April 2021

AbstractFullPdf
Apr 202118017768
Total18017768